NeoChord, Inc., a venture backed medical device company, is investigating minimally invasive technology intended to transform the treatment of mitral regurgitation.

Learn More

Latest Developments and Events

  • Three patient enrollments in TACT Trial on February 20, 2012

    Three NeoChord procedures were successfully performed at Santariskiu Clinic by Dr. Audrius Aidietis on Feb. 20, 2012. The procedures were proctored by the inventor of the NeoChord device, Giovanni Speziali, MD, University of Pittsburgh Medical Center.

    - Click for More News -

  • NeoChord Committed to Maintaining ISO Certification

    NeoChord initially obtained ISO 13485:2003 Quality Management System Certification in 2010 through BSI. Most recently, in February 2012, BSI conducted a surveillance audit and reaffirmed NeoChord continues compliance with these ISO requirements.

Caution: The NeoChord device is an investigational device and is NOT AVAILABLE FOR COMMERCIAL USE.